Wang Xianyao, Shi Rongjie, Zi Ying, Long Jun
Department of Gastroenterology, The First Affiliated Hospital of Dali University, Dali, Yunnan, China.
Front Nutr. 2024 Nov 8;11:1486898. doi: 10.3389/fnut.2024.1486898. eCollection 2024.
Sarcopenia is a common complication of fatty liver, and sarcopenia increases the risk of advanced liver fibrosis in patients with Metabolic dysfunction-associated fatty liver disease (MAFLD). Chronic inflammation is the crucial link between sarcopenia and fatty liver. An anti-inflammatory diet is expected to be an essential measure to prevent sarcopenia in patients with fatty liver, and the dietary inflammatory index (DII) is a crucial tool for assessing the inflammatory potential of diets. However, the relationship between DII and sarcopenia in patients with fatty liver is unclear.
This study investigated the correlation between the dietary inflammatory index (DII) and sarcopenia in patients with Metabolic dysfunction-associated fatty liver disease (MAFLD).
Data for this study were obtained from the National Health and Nutrition Examination Survey (NHANES) 2017-2018, with 917 patients with MAFLD participating in the study. Participants were divided into three groups based on DII tertiles: group T1 ( = 305), group T2 ( = 306), and group T3 ( = 306), and binary logistic regression was used to assess the relationship between DII and sarcopenia with stratified analyses based on the weights recommended by the NHANES and multivariate linear regression was used to evaluate the association of DII with total appendicular lean mass.
After adjusting for all confounders, DII was significantly and positively associated with the risk of sarcopenia in women [OR: 1.61, 95% CI: (1.226, 2.06), < 0.001]. The risk of sarcopenia was higher in the T3 group compared to the T1 group [OR: 4.04, 95% CI: (1.66, 9.84), = 0.002]. DII was negatively associated with appendicular lean mass adjusted for body mass index in both men and women.
DII was significantly associated with the risk of sarcopenia in female patients with MAFLD, with higher DII scores related to a higher risk of sarcopenia. Higher DII scores related to a higher risk of sarcopenia in men with significant fibrosis.
肌肉减少症是脂肪肝的常见并发症，且肌肉减少症会增加代谢功能障碍相关脂肪性肝病（MAFLD）患者发生晚期肝纤维化的风险。慢性炎症是肌肉减少症与脂肪肝之间的关键联系。抗炎饮食有望成为预防脂肪肝患者肌肉减少症的重要措施，而饮食炎症指数（DII）是评估饮食炎症潜力的关键工具。然而，脂肪肝患者中DII与肌肉减少症之间的关系尚不清楚。
本研究调查了代谢功能障碍相关脂肪性肝病（MAFLD）患者的饮食炎症指数（DII）与肌肉减少症之间的相关性。
本研究的数据来自2017 - 2018年美国国家健康与营养检查调查（NHANES），有917例MAFLD患者参与了该研究。参与者根据DII三分位数分为三组：T1组（n = 305）、T2组（n = 306）和T3组（n = 306），采用二元逻辑回归评估DII与肌肉减少症之间的关系，并根据NHANES推荐的权重进行分层分析，采用多元线性回归评估DII与总四肢瘦体重的关联。
在调整所有混杂因素后，DII与女性肌肉减少症风险显著正相关[比值比（OR）：1.61，95%置信区间（CI）：（1.226，2.06），P < 0.001]。与T1组相比，T3组肌肉减少症风险更高[OR：4.04，95%CI：（1.66，9.84），P = 0.002]。在男性和女性中，调整体重指数后，DII与四肢瘦体重呈负相关。
DII与MAFLD女性患者的肌肉减少症风险显著相关，DII评分越高，肌肉减少症风险越高。在有显著纤维化的男性中，DII评分越高，肌肉减少症风险越高。
